S
Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases
About Stoke Therapeutics
Stoke Therapeutics is at the forefront of developing innovative treatments for severe genetic diseases. The company focuses on conditions caused by the loss of function in a single gene, aiming to restore missing proteins through precise upregulation of protein expression. Stoke Therapeutics operates primarily in the biotechnology and pharmaceutical markets, targeting patients with rare genetic disorders. Their business model revolves around the research and development of disease-modifying therapies, leveraging their proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform allows them to deliver highly precise, durable, and controllable treatments to a broad range of tissues. Stoke Therapeutics generates revenue through partnerships, licensing agreements, and eventually, the commercialization of their therapies. The company serves a niche market of patients with unmet medical needs, providing hope for those affected by debilitating genetic conditions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Bedford, United States
- Listing
- IPO 2019
- Employees
- 219
- Open positions
- 16
- Dealroom signal
- 91.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2024 | $125M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Nov 2020 | $105M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $184M | 0% | −$19M | -10.2% |
| 2025 | $184M | +404.5% | −$19M | -10.2% |
| 2024 | $37M | +316.3% | −$99M | -271.4% |
| 2023 | $8.8M | -29.2% | −$112M | -1279.1% |
| 2022 | $12M | — | −$104M | -841.2% |
| 2021 | $0 | — | −$86M | — |
| 2020 | $0 | — | −$53M | — |
Growth signals
Latest recorded traffic for Stoke Therapeutics is 13K monthly website visits, down 18.8% over the last three months. Stoke Therapeutics's team grew 41.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Apple Tree Partners
RTW Investments
Alexandria Venture Investments
Cormorant Asset Management
RA Capital Management
Perceptive Advisors
Other known investors1 additional known investor
Cold Spring Harbor Laboratory
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stoke Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stoke Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.